Kalbe Farma Tbk PT - Asset Resilience Ratio

Latest as of June 2025: 6.34%

Kalbe Farma Tbk PT (KLBF) has an Asset Resilience Ratio of 6.34% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Kalbe Farma Tbk PT to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Rp1.87 Trillion
≈ $109.61 Million USD Cash + Short-term Investments

Total Assets

Rp29.51 Trillion
≈ $1.73 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2000–2024)

This chart shows how Kalbe Farma Tbk PT's Asset Resilience Ratio has changed over time. See KLBF net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Kalbe Farma Tbk PT's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Kalbe Farma Tbk PT worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rp1.72 Trillion 5.84%
Short-term Investments Rp148.38 Billion 0.5%
Total Liquid Assets Rp1.87 Trillion 6.34%

Asset Resilience Insights

  • Limited Liquidity: Kalbe Farma Tbk PT maintains only 6.34% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kalbe Farma Tbk PT Industry Peers by Asset Resilience Ratio

Compare Kalbe Farma Tbk PT's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Pfizer Inc
NYSE:PFE
Drug Manufacturers - General 5.48%
AstraZeneca PLC
NYSE:AZN
Drug Manufacturers - General 0.10%
Roche Holding AG
SW:ROG
Drug Manufacturers - General 15.37%
Hunan Jingfeng Pharmaceutical
SHE:000908
Drug Manufacturers - General 0.38%
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Drug Manufacturers - General 7.83%
Firebrick Pharma Ltd
AU:FRE
Drug Manufacturers - General 0.29%
Eli Lilly and Company
SA:LILY34
Drug Manufacturers - General 8.63%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 5.48%

Annual Asset Resilience Ratio for Kalbe Farma Tbk PT (2000–2024)

The table below shows the annual Asset Resilience Ratio data for Kalbe Farma Tbk PT.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 10.98% Rp3.23 Trillion
≈ $189.32 Million
Rp29.43 Trillion
≈ $1.72 Billion
+3.30pp
2023-12-31 7.68% Rp2.08 Trillion
≈ $121.77 Million
Rp27.06 Trillion
≈ $1.59 Billion
-1.35pp
2022-12-31 9.03% Rp2.46 Trillion
≈ $144.18 Million
Rp27.24 Trillion
≈ $1.60 Billion
-4.93pp
2021-12-31 13.96% Rp3.58 Trillion
≈ $209.93 Million
Rp25.67 Trillion
≈ $1.50 Billion
+0.35pp
2020-12-31 13.61% Rp3.07 Trillion
≈ $179.97 Million
Rp22.56 Trillion
≈ $1.32 Billion
+2.48pp
2019-12-31 11.13% Rp2.26 Trillion
≈ $132.15 Million
Rp20.26 Trillion
≈ $1.19 Billion
-2.91pp
2018-12-31 14.03% Rp2.55 Trillion
≈ $149.23 Million
Rp18.15 Trillion
≈ $1.06 Billion
+1.26pp
2017-12-31 12.78% Rp2.12 Trillion
≈ $124.39 Million
Rp16.62 Trillion
≈ $973.65 Million
-3.45pp
2016-12-31 16.22% Rp2.47 Trillion
≈ $144.75 Million
Rp15.23 Trillion
≈ $892.18 Million
+15.09pp
2015-12-31 1.14% Rp155.75 Billion
≈ $9.13 Million
Rp13.70 Trillion
≈ $802.56 Million
-0.47pp
2014-12-31 1.60% Rp199.39 Billion
≈ $11.68 Million
Rp12.43 Trillion
≈ $728.06 Million
-0.05pp
2013-12-31 1.66% Rp187.74 Billion
≈ $11.00 Million
Rp11.32 Trillion
≈ $663.02 Million
-0.77pp
2012-12-31 2.43% Rp229.12 Billion
≈ $13.43 Million
Rp9.42 Trillion
≈ $551.85 Million
+1.06pp
2011-12-31 1.38% Rp113.87 Billion
≈ $6.67 Million
Rp8.27 Trillion
≈ $484.86 Million
+1.30pp
2010-12-31 0.08% Rp5.32 Billion
≈ $311.49K
Rp7.03 Trillion
≈ $412.08 Million
-0.89pp
2009-12-31 0.97% Rp62.60 Billion
≈ $3.67 Million
Rp6.48 Trillion
≈ $379.85 Million
-1.22pp
2008-12-31 2.19% Rp124.75 Billion
≈ $7.31 Million
Rp5.70 Trillion
≈ $334.22 Million
-1.23pp
2007-12-31 3.42% Rp175.83 Billion
≈ $10.30 Million
Rp5.14 Trillion
≈ $301.08 Million
-2.19pp
2006-12-31 5.62% Rp259.70 Billion
≈ $15.22 Million
Rp4.62 Trillion
≈ $270.98 Million
-13.44pp
2005-12-31 19.06% Rp882.99 Billion
≈ $51.74 Million
Rp4.63 Trillion
≈ $271.50 Million
-17.51pp
2004-12-31 36.57% Rp1.10 Trillion
≈ $64.65 Million
Rp3.02 Trillion
≈ $176.78 Million
+6.24pp
2003-12-31 30.33% Rp742.67 Billion
≈ $43.52 Million
Rp2.45 Trillion
≈ $143.47 Million
+15.45pp
2002-12-31 14.88% Rp299.97 Billion
≈ $17.58 Million
Rp2.02 Trillion
≈ $118.10 Million
+13.48pp
2001-12-31 1.41% Rp26.39 Billion
≈ $1.55 Million
Rp1.88 Trillion
≈ $110.00 Million
-5.44pp
2000-12-31 6.84% Rp120.31 Billion
≈ $7.05 Million
Rp1.76 Trillion
≈ $103.00 Million
--
pp = percentage points

About Kalbe Farma Tbk PT

JK:KLBF Indonesia Drug Manufacturers - General
Market Cap
$1.96 Billion
Rp33.53 Trillion IDR
Market Cap Rank
#6341 Global
#52 in Indonesia
Share Price
Rp740.00
Change (1 day)
+2.07%
52-Week Range
Rp665.00 - Rp1595.00
All Time High
Rp2271.54
About

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more